-

 

Metabolic Disorders, Ageing and Aflatoxicosis 

Abstract

Chronic exposure to aflatoxins — particularly Aflatoxin B1 (AFB1) and its metabolites such as Aflatoxin M1 (AFM1) — remains a major public-health threat in many low- and middle-income countries, especially in sub-Saharan Africa and other tropical regions. While the carcinogenicity of aflatoxins (notably hepatocellular carcinoma and liver cirrhosis) is well established, increasing evidence suggests that aflatoxin exposure may also contribute to metabolic disorders (e.g. type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease [NAFLD] / metabolically associated steatotic liver disease [MASLD]), influence growth and development in early life, and may have long-term effects on biological ageing, metabolic resilience, and organ-system health. The mechanisms appear to involve disruption of liver metabolism, gut-microbiota alterations, inflammation, oxidative stress, endocrine and signalling perturbations, and possibly epigenetic changes. Given the rising global burden of metabolic disease, the overlap with high-aflatoxin exposure populations represents an under-recognized public health challenge. This review synthesizes current evidence, identifies gaps, and proposes integrated research and policy actions — especially relevant for regions like East Africa (e.g., Kenya) — to reduce exposure and mitigate long-term metabolic and ageing-related health impacts.

1. Background: Aflatoxins and Public Health

  • Aflatoxins are a group of mycotoxins produced by certain fungi (notably species of Aspergillus) that can contaminate staple crops (maize, groundnuts, sorghum, cassava among others), especially under hot, humid conditions or poor post-harvest storage. Juniper Publishers+2Wikipedia+2

  • The most studied and most toxic of these is Aflatoxin B1 (AFB1), which is metabolized in the liver via cytochrome P450 enzymes into a reactive epoxide that can form DNA adducts, causing mutations (e.g., in tumour suppressor genes like p53) — the basis for its carcinogenic risk. Wikipedia+2NCBI+2

  • Chronic exposure may not always reach the levels causing acute aflatoxicosis; more often, people suffer prolonged, low-level exposure via diet. Such exposures have cumulative effects over time, including possible carcinogenic, immunotoxic, developmental, and metabolic consequences. NCBI+1

  • Some aflatoxin metabolites, like AFM1, can be found in milk and dairy products when animals or humans consume contaminated feed or food, rendering even processed milk a potential source of exposure. EKB Journals+1

Given the heavy reliance on staples like maize and groundnuts, and in many settings limited capacity for rigorous food safety and storage, chronic aflatoxin exposure remains widespread — especially in tropical and subtropical regions. This makes the public-health implications far broader than cancer alone.

2. Emerging Evidence: Aflatoxin and Metabolic Disorders

While historically research has focused on carcinogenicity, more recent studies — both observational and experimental — suggest links between aflatoxin exposure and metabolic dysregulation.

2.1 Human / Epidemiologic Data

  • A cross-sectional study of 423 individuals in Guatemala measured serum AFB1–albumin adducts and assessed metabolic conditions: diabetes, obesity, central obesity, metabolic syndrome, and NAFLD. The authors found a statistically significant association between high AFB1-adduct levels and type 2 diabetes: individuals in the highest adduct quartile had a prevalence odds ratio (POR) of 3.74 (95% CI: 1.71–8.19; p-trend = 0.003) compared with the lowest quartile. PMC+1

  • No significant associations were seen in that study between AFB1 adducts and obesity, central obesity, metabolic syndrome or NAFLD — but the diabetes association was the first evidence in humans linking AFB1 to metabolic disease. PMC+1

  • Other human investigations have looked at AFM1 exposure (e.g. via milk) and metabolic risk factors: one study with 672 participants found that those with detectable AFM1 had higher prevalence of type 2 diabetes, and that AFM1 levels correlated with markers of inflammation, oxidative stress, impaired insulin secretion and altered carbohydrate metabolism. PubMed

  • Studies from clinical populations (e.g. in Baghdad Province) suggest that among people with type 2 diabetes, those “carrying” AFB1 have worse glycemic control (higher fasting blood glucose, HbA1c) and impaired liver/kidney parameters compared with diabetics without detectable AFB1; the authors interpret this as AFB1 exacerbating metabolic disease and its complications. journal.nuc.edu.iq+1

Taken together, although human data remain limited and cannot definitively prove causality, the associations with type 2 diabetes and glycemic dysregulation are concerning — especially given the heavy burden of aflatoxin exposure in many low-resource regions.

2.2 Experimental & Mechanistic Studies

  • In a cell-line study, AFB1 was shown to activate the insulin-like growth factor 1 receptor (IGF-IR) signalling cascade in human liver-derived cells (HepG2, Chang liver), including downstream activation of Akt and ERK pathways; at the same time AFB1 downregulated insulin receptor substrate 1 (IRS1) but upregulated IRS2. PubMed This suggests that AFB1 can directly perturb insulin/IGF signalling — potentially contributing to metabolic dysregulation, aberrant cell proliferation, and altered metabolism.

  • Animal models highlight another important dimension: gut–liver–microbiota interactions. A study in male F344 rats exposed to AFB1 (various doses) for 4 weeks found dramatic alterations in the gut microbiota–dependent metabolome: reduced short-chain fatty acids (SCFAs) (> 70% reduction at high dose), disrupted bile acid metabolism, and changes in amino acid and lipid-related pathways. OUP Academic+1

    • SCFAs (e.g., butyrate, acetate) are important for gut health, immune regulation, and metabolic homeostasis; their reduction may impair gut barrier integrity, promote inflammation, and alter energy metabolism.

    • Disrupted bile-acid and lipid metabolism may compromise hepatic and systemic metabolic regulation, promote lipid accumulation, insulin resistance, and inflammatory states.

  • More recently, a murine study combining a high-fat diet (HFD) with AFB1 exposure showed that while AFB1 alone produced minimal metabolic disturbance, the combination synergistically worsened hepatic steatosis, promoted intestinal barrier disruption, Th17-mediated inflammation, and metabolic disruption. PubMed+1 This suggests that baseline nutritional context (e.g., high-fat diet) may exacerbate the metabolic toxicity of aflatoxin.

  • Additionally, evidence implicates impaired immune signalling: AFB1 was shown to suppress type I interferon (IFN) response (downregulating JAK1, STAT1, OAS3) in vitro, which may impair innate immunity and contribute to chronic inflammation or inadequate responses to other stressors. SpringerLink

These mechanistic and experimental data — from signalling pathways, gut-microbiota metabolism, inflammation, lipid homeostasis, and diet-toxin interactions — provide plausible biological pathways by which chronic aflatoxin exposure may contribute to metabolic disorders, beyond carcinogenicity.

3. Link with Liver Disease, Ageing and Life-course Outcomes

3.1 Liver disease and metabolic-liver interplay

  • Aflatoxin exposure is strongly linked to chronic liver disease: a systematic review and meta-analysis showed that people exposed to aflatoxins have a significantly higher risk of liver cirrhosis (adjusted pooled OR ≈ 2.5; unadjusted OR ≈ 3.35) compared to non-exposed. PubMed+1

  • At the same time, metabolic-liver disease — including non-alcoholic fatty liver disease (NAFLD), now more broadly conceptualized as Metabolic dysfunction-associated steatotic liver disease (MASLD) — is experiencing a global rise, tracking with increases in obesity, type 2 diabetes, and metabolic syndrome. PubMed+1

  • The pathogenesis of MASLD involves insulin resistance, lipogenesis, adipokine dysregulation, oxidative stress, pro-inflammatory cytokines, mitochondrial dysfunction, and gut-liver axis perturbations (e.g., altered microbiota/bile acid metabolism) — many of which overlap mechanistically with pathways that could be triggered or exacerbated by aflatoxin exposure. aps.journals.ekb.eg+2PubMed+2

  • Importantly, MASLD is not just a liver disease — it predisposes to cardiovascular disease, chronic kidney disease, systemic inflammation, and may accelerate biological ageing. PubMed+1

Thus, in populations with high aflatoxin exposure plus emerging burdens of metabolic risk (e.g., urbanizing diets, obesity), there may be a convergence: aflatoxin-driven hepatic injury + metabolic-liver disease + systemic metabolic syndrome — potentially speeding up morbidity, multimorbidity, and premature ageing.

3.2 Early-life exposure, growth impairment, and developmental/aging consequences

  • A recent meta-analysis (2023) of studies assessing AFB1 exposure in infants/children found that higher exposure is associated with worse growth outcomes: pooled data showed negative associations with weight-for-age (WAZ) and height-for-age (HAZ) z-scores, and in cohort studies increased odds of underweight (OR ~ 1.20) and stunting (OR ~ 1.21). SpringerLink+1

  • The mechanisms are likely multifactorial: AFB1 may impair gut integrity, nutrient absorption, protein synthesis (e.g., via liver dysfunction), metabolic regulation (e.g., insulin/IGF axis), and immune competence — thereby compromising growth, development, and possibly programming long-term metabolic vulnerability. SpringerLink+2OUP Academic+2

  • Early-life insults (poor growth, impaired organ development) coupled with ongoing exposure may predispose to earlier onset of metabolic diseases, accelerate biological ageing, reduce physiological reserve, and increase risk of chronic disease across the life-course.

4. Why Aflatoxicosis + Metabolic Disease Matters — Public Health & Development Perspective

  • In many low- and middle-income countries (LMICs), populations already face undernutrition, infectious disease burden, limited health infrastructure, and now an emerging wave of non-communicable diseases (NCDs) including diabetes, obesity, and MASLD. Adding aflatoxin-driven metabolic insults may compound vulnerabilities.

  • Because aflatoxin exposure is often chronic, low-level, and affects large populations (via staple foods or contaminated milk), the population attributable burden may be substantial — even if individual risk increase seems modest. This is especially important for food security contexts: aflatoxin control must balance with improving nutritional access.

  • Early-life exposure may have “legacy effects”: poor growth, developmental deficits, epigenetic modifications, increased susceptibility to metabolic disease — thereby contributing to intergenerational cycles of vulnerability, poor health, and early ageing.

  • From a health-systems standpoint, co-morbidities (e.g., liver disease + diabetes + MASLD) increase complexity and cost of care; but aflatoxin exposure prevention (agricultural + food-safety + storage + regulation) may be a cost-effective upstream intervention.

5. Proposed Mechanistic Model (Synthesis)

Here is a simplified conceptual model to guide future research and intervention design:

Chronic dietary exposure → AFB1 (and AFM1) uptake →
   • Liver metabolism: AFB1 biotransformation → reactive epoxide → DNA adducts → hepatocyte injury / dysfunction → impaired glucose & lipid metabolism → insulin resistance / dyslipidaemia → MASLD / NAFLD → metabolic syndrome / T2DM.
   • Direct interference with insulin/IGF signalling (IGF-IR / IRS2 up-regulation) → dysregulated growth and metabolic control.
   • Gut–microbiota disruption: reduced SCFAs, altered bile acids, dysbiosis → impaired gut barrier, inflammation, altered energy/nutrient metabolism → metabolic and immune stress.
   • Chronic low-grade inflammation + oxidative stress → systemic metabolic stress, organ damage, accelerated biological ageing.
   • Early-life exposure → impaired growth / development, reduced physiologic reserve → life-course increased vulnerability to metabolic and age-related disease.

6. Key Research Gaps & Priorities

To better understand and act on the link between aflatoxicosis, metabolic disorders and ageing, the following research priorities stand out:

  1. Prospective cohort studies in high-exposure settings (e.g., sub-Saharan Africa) that track aflatoxin biomarkers (AFB1 adducts, AFM1) alongside metabolic parameters (glucose, insulin resistance, lipid profile, liver function), liver-imaging/steatosis markers, and ageing biomarkers (e.g., telomere length, epigenetic clocks).

  2. Dose–response characterization of chronic low-level exposure: many animal studies use relatively high doses; more realistic, low-dose, long-duration exposure models would better reflect human contexts.

  3. Interventional studies: e.g., trials of dietary diversity, antioxidant/nutrient supplementation, or food-safety interventions (storage, sorting, decontamination) — measuring metabolic outcomes, liver health, growth (in children), and biomarkers of oxidative stress/inflammation.

  4. Mechanistic human studies: exploring how AFB1 affects insulin/IGF signalling, hepatic glucose/lipid metabolism, gut microbiota composition and metabolome, nutrient absorption, and immune function in exposed populations.

  5. Mixed-methods and policy-relevant research: socio-economic, cultural, and structural determinants of aflatoxin exposure (storage practices, food supply chains, regulatory enforcement, dietary patterns), and modeling the public-health impact of combined aflatoxin-metabolic disease burden.

7. Policy & Public-Health Recommendations (Enhanced)

Given the evidence and plausible risks, here are expanded and refined policy and public-health recommendations — especially relevant for LMICs and regions like East Africa:

  1. Integrate aflatoxin exposure surveillance into national NCD and maternal-child health programs: use biomarkers (e.g., AFB1–albumin adducts, AFM1 in milk) in sentinel cohorts (pregnant women, children, diabetic patients) to monitor exposure and health outcomes.

  2. Strengthen agricultural, storage, and food-safety systems: Promote good agronomic practices, use of atoxigenic biocontrol strains, proper drying, safe/ hermetic storage, and sorting of foods; support smallholder farmers with subsidies or access to safer storage technology.

  3. Promote dietary diversification and nutrient-rich diets: Encourage inclusion of foods less susceptible to aflatoxin contamination where possible, and strengthen access to antioxidant- and micronutrient-rich foods (fruits, vegetables) that may help mitigate oxidative stress.

  4. Public education and risk communication: Raise awareness at community level about risks of aflatoxin, safer storage and food-handling, and the importance of varied diet — tailoring messages to cultural and socio-economic contexts.

  5. Health system preparedness and screening: Train clinicians to consider environmental toxins (like aflatoxin) when managing metabolic disease, liver disease, or growth disorders; integrate liver function testing, metabolic screening, and nutritional counselling in high-risk areas.

  6. Regulatory and trade policy balancing: Develop context-appropriate regulatory limits, combining food-safety standards with food security concerns. Support smallholder producers to meet safety standards without marginalization.

  7. Cross-sectoral coordination and financing: Establish national/regional task forces for mycotoxin control combining agriculture, health, trade, and social protection sectors; leverage international funding, development aid, and private-sector partnerships to invest in storage infrastructure, biocontrol, surveillance, and community interventions.

8. Implications for Aging, Equity and Long-Term Development

  • Aflatoxin-driven metabolic and hepatic damage may contribute to premature biological ageing, reduced life expectancy, and increased risk of age-related comorbidities (cardiovascular disease, kidney disease, frailty) — especially in populations with repeated exposure over life.

  • Early-life exposure and growth stunting may have intergenerational consequences: poor growth + metabolic programming may predispose to early onset of NCDs, perpetuating cycles of vulnerability, poverty, and ill health.

  • Addressing aflatoxin exposure is a social justice and equity issue: often the poorest and most food-insecure — who depend heavily on dietary staples — are most exposed, yet they also have the least access to health care and nutritional variety. Interventions must be designed with this equity dimension in mind.

  • From a developmental economics perspective, reducing aflatoxin exposure may yield large long-term returns: improved population health, reduced NCD burden, enhanced workforce productivity, and decreased health-care costs.

9. Conclusion

The conventional view of aflatoxins as primarily carcinogenic toxins — causing liver cancer and acute toxicity — is too narrow. Emerging evidence indicates that chronic aflatoxin exposure may also contribute to metabolic disorders, liver-metabolic disease (MASLD/NAFLD), impaired growth and development, and may amplify the burden of NCDs in vulnerable populations. Given global trends (nutrition transition, rising obesity and diabetes, persistent food insecurity and reliance on staples), this convergence may pose a growing but under-recognized public-health challenge — especially in sub-Saharan Africa and other aflatoxin-endemic regions.

Proactive, integrated, cross-sectoral action — combining agriculture, public health, nutrition, trade and social policy — is essential. Equally important is building a stronger evidence base: prospective cohort studies, intervention trials, mechanistic research, and policy-relevant analysis.

Ignoring the metabolic and ageing dimension of aflatoxicosis risks underestimating the full burden of disease, perpetuating cycles of poor health, malnutrition, and early morbidity in vulnerable communities.

Selected References

  • Alvarez CS, Rivera-Andrade A, Kroker-Lobos MF, et al. “Associations between aflatoxin B1-albumin adduct levels with metabolic conditions in Guatemala: A cross-sectional study.” Health Science Reports. 2022. PMC+1

  • Study on AFM1 exposure and metabolic risk factors (n = 672). PubMed

  • Sirhan AE, Al-Jumaily SA. “The Role of Aflatoxin B1 in the Exacerbation of Type 2 Diabetes and its Effects on Liver and Kidney Functions.” Al-Nisour Journal for Medical Sciences. 2024. journal.nuc.edu.iq+1

  • U((rats) F344) study of gut-microbiota metabolome disruption by AFB1. OUP Academic+1

  • Combined high-fat diet + AFB1 exposure in mice: immunometabolic disruption, hepatic steatosis, gut-liver axis breakdown. PubMed+1

  • Review: molecular mechanisms of NAFLD / metabolic-liver disease and its link to metabolic syndrome & NCDs. PubMed+2aps.journals.ekb.eg+2

  • Meta-analysis: AFB1 exposure in early life and growth impairment (infants/children). SpringerLink+1

  • Aflatoxin exposure and risk of liver cirrhosis (systematic review + meta-analysis). PubMed+1

 

Comments

Post a Comment

Popular posts from this blog

-
  Impacts of Pit Latrine Waste on Early Puberty in Africa Introduction Across sub-Saharan Africa, pit latrines serve as the primary sanitation infrastructure for over 50% of urban populations and an even higher proportion in rural areas, providing a low-cost solution to the challenge of open defecation. These simple, often unlined pits collect human waste but pose significant risks to environmental and public health due to potential groundwater contamination. Emerging evidence suggests that chemical pollutants from pit latrines, particularly endocrine-disrupting chemicals (EDCs), may contribute to early puberty in children, especially girls, with far-reaching health, social, and educational consequences. Early puberty, defined as pubertal development before age 8 in girls or 9 in boys, is associated with increased risks of mental health disorders, reproductive health issues, and socioeconomic challenges, particularly in resource-constrained settings. In Africa, where sanitation inf...
Read more
-
  Health insurance affordability and the quality of life among low Socioeconomic Status (SES) individuals in Low- and Middle-Income Countries (LMICs)   Preamble: Whereas the right to health is a fundamental human right, it remains inaccessible to many, especially those of low socioeconomic status (SES) in low- and middle-income countries (LMICs); and whereas the affordability of health insurance is a critical factor that can enhance or impede access to necessary healthcare services; we recognize that the ability to obtain health insurance plays a pivotal role in determining the quality of life for individuals and families within these communities. Acknowledging that the lack of affordable health insurance options leads to a disproportionate burden of disease and financial hardship on low SES populations; and understanding that the provision of affordable health insurance is not only a matter of social justice but also an investment in the social and economic development ...
Read more
-
Child Health:  Dealing with Aflatoxins in Children’s Food Aflatoxins, produced primarily by Aspergillus flavus and A. parasiticus , are highly toxic and carcinogenic mycotoxins that contaminate key food crops in tropical and subtropical regions. In low- and middle-income countries (LMICs), especially across sub-Saharan Africa, chronic exposure to aflatoxins in staple foods poses grave health risks for children, including growth impairment, immunosuppression, developmental deficits, and increased vulnerability to infectious diseases. This paper explores the sources of aflatoxin contamination in children's food, its public health impacts, and proposes multisectoral policies and interventions to protect child health and nutrition, with a focus on evidence from Africa. 1. Introduction Aflatoxin contamination is one of the most pressing yet under-addressed food safety challenges affecting children in LMICs. Staple foods such as maize, sorghum, groundnuts, and dairy products are pro...
Read more